1223 Cost-effectiveness of radium-223 compared to best standard of care, abiraterone acetate and enzalutamide in the treatment of castration resistant prostate cancer in the Netherlands

2015 ◽  
Vol 51 ◽  
pp. S179-S180
Author(s):  
C. De Meijer ◽  
A. Baka ◽  
A. Leliveld-Kors ◽  
W. Noordzij ◽  
J. Gaultney
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
The Netherlands ◽  
Standard Of Care ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223

Novel therapies and emerging strategies for the treatment of patients with castration-resistant prostate cancer

2017 ◽  
Author(s):  
Deborah Mukherji ◽  
Aurelius Omlin ◽  
Carmel Pezaro ◽  
Johann De Bono
Keyword(s):  
Prostate Cancer ◽  
Abiraterone Acetate ◽  
Phase Iii ◽  
Trial Participation ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
New Treatments ◽  
Phase Iii Studies ◽  
Clinical And Translational Research

Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phase III studies for patients with metastatic CRPC. Furthermore, multiple agents and combinations are currently in late-stage clinical testing. Men with advanced prostate cancer represent an important population for clinical and translational research and clinical trial participation should be considered as part of standard care.

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective

2012 ◽  
Vol 08 (02) ◽  
pp. 89
Author(s):  
Guru Sonpavde ◽  
E David Crawford ◽  
◽  
Keyword(s):  
Prostate Cancer ◽  
Abiraterone Acetate ◽  
Chemotherapeutic Agents ◽  
New Drugs ◽  
Phase Iii ◽  
Castration Resistant Prostate Cancer ◽  
Microtubule Inhibitor ◽  
Phase Iii Clinical Trials ◽  
Castration Resistant ◽  
Radium 223

Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have shown significant improvements in survival—over mitoxantrone (for cabazitaxel) and over placebo (for sipuleucel-T and abiraterone acetate)—and were well tolerated. There are also two treatments in late-stage development, MDV3100 (an oral AR antagonist) and radium-223 (an isotope that creates breaks in double-stranded DNA). These have also shown improvements in survival in Phase III trials; their regulatory approval is expected soon. The modes of actions of the existing and new drugs in CRPC are varied, but some are complementary and investigations of different combinations of these medications are much needed; they may enhance efficacy, further extend survival, and improve outcomes in this formerly untreatable disease.

Management of Castration-Resistant Prostate Cancer: First-Line Therapy

2019 ◽  
Author(s):  
Simon Y.F. Fu ◽  
Kim N. Chi
Keyword(s):  
Prostate Cancer ◽  
Abiraterone Acetate ◽  
Chemotherapeutic Agents ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
First Line Therapy ◽  
Castration Resistant ◽  
Radium 223 ◽  
Incurable Condition ◽  
Line Setting

The development of castration-resistant prostate cancer (CRPC) heralds significant morbidity and an incurable condition. Since 2004, there are now six proven life-prolonging therapies available, including androgen receptor pathway inhibitor (ARPI) , chemotherapeutic agents, radiopharmaceutical, and immunotherapy for the first-line management of metastatic CRPC. Recent advances have seen enzalutamide and apalutamide approved by US FDA for the treatment of nonmetastatic CRPC, with darolutamide the latest ARPI demonstrating efficacy in nonmetastatic CRPC. ARPI is the treatment of choice in the first-line setting for most CRPC patients, and this approach has been endorsed by clinical guidelines and expert consensus, although treatment must be individualized. Advances in the molecular profiling of CRPC promise to select suitable patients for trials involving targeted therapy and identify biomarkers to guide treatment selection. This review contains 2 figures, 1 table, and 54 references. Keywords: abiraterone acetate, apalutamide, cabazitaxel, castration-resistant prostate cancer, docetaxel, enzalutamide, first-line treatment, radium-223, sipuleucel-T

Sign in / Sign up

Export Citation Format

Share Document